9920 Pacific Heights Boulevard
Suite 350
San Diego, CA 92121
United States
858 704 4660
https://www.vikingtherapeutics.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 28
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Brian Lian Ph.D. | President, CEO & Director | 987,1k | S.O. | 1966 |
Mr. Gregory S. Zante | Chief Financial Officer | 655k | S.O. | 1971 |
Ms. Marianne Mancini | Chief Operating Officer | 670k | S.O. | 1965 |
Mr. Michael Morneau | Vice President of Finance & Administration | 375,33k | S.O. | 1965 |
Dr. Geoffrey E. Barker Ph.D. | Senior Vice President of Pharmaceutical Development | S.O. | S.O. | S.O. |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
L’ISS Governance QualityScore de Viking Therapeutics, Inc. en date du 1 juin 2024 est 8. Les scores principaux sont Audit : 8; Société : 8; Droits des actionnaires : 8; Compensation : 8.